Evercore Wealth Management LLC Has $11.63 Million Stock Holdings in Stryker Co. (NYSE:SYK)

Evercore Wealth Management LLC trimmed its position in Stryker Co. (NYSE:SYK) by 0.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 32,304 shares of the medical technology company’s stock after selling 51 shares during the period. Evercore Wealth Management LLC’s holdings in Stryker were worth $11,631,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Morse Asset Management Inc grew its holdings in Stryker by 16.5% during the 3rd quarter. Morse Asset Management Inc now owns 1,410 shares of the medical technology company’s stock worth $509,000 after acquiring an additional 200 shares during the period. World Investment Advisors LLC boosted its position in shares of Stryker by 126.1% in the 3rd quarter. World Investment Advisors LLC now owns 8,142 shares of the medical technology company’s stock worth $2,941,000 after purchasing an additional 4,541 shares during the last quarter. Arvest Bank Trust Division acquired a new stake in shares of Stryker during the third quarter worth $245,000. Wilmington Savings Fund Society FSB increased its holdings in Stryker by 13.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 44,795 shares of the medical technology company’s stock valued at $16,183,000 after purchasing an additional 5,361 shares during the last quarter. Finally, Tidal Investments LLC lifted its stake in Stryker by 13.9% in the third quarter. Tidal Investments LLC now owns 17,478 shares of the medical technology company’s stock valued at $6,314,000 after buying an additional 2,139 shares during the period. 77.09% of the stock is owned by institutional investors.

Stryker Stock Up 2.7 %

Stryker stock opened at $348.62 on Wednesday. The company has a fifty day simple moving average of $369.25 and a 200 day simple moving average of $373.06. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a market cap of $133.06 billion, a P/E ratio of 44.93, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the company earned $3.46 EPS. Research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.96%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is presently 43.30%.

Insider Activity at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of recent analyst reports. Argus set a $450.00 price target on Stryker in a research note on Monday, February 3rd. JMP Securities reiterated a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. BTIG Research set a $403.00 price target on shares of Stryker and gave the company a “buy” rating in a report on Monday, April 14th. Royal Bank of Canada raised their price objective on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 29th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $442.00 target price on shares of Stryker in a research note on Friday, March 21st. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $423.53.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.